UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 11, 2011 (November 11, 2011)
Endo Pharmaceuticals Holdings Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-15989 | 13-4022871 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
100 Endo Boulevard, Chadds Ford, PA | 19317 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code (610) 558-9800
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. | Other Events. |
On November 11, 2011, Endo Pharmaceuticals Holdings Inc. (the Company) decided to terminate the development of its octreotide implant for the treatment of acromegaly. The decision was made after conducting an in-depth review of the Companys research and development activities, including an analysis of research and development priorities, focus and available resources for current and future projects and the commercial potential for the product.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ENDO PHARMACEUTICALS HOLDINGS INC. | ||
(Registrant) | ||
By: | /s/ CAROLINE B. MANOGUE | |
Name: | Caroline B. Manogue | |
Title: | Executive Vice President, Chief Legal Officer & Secretary |
Dated: November 11, 2011